| Literature DB >> 34302225 |
Snehalatha Basavaraju1, Jamuna Bai Aswathanarayan2, Madhu Basavegowda3, Balasubramanian Somanathan1.
Abstract
The coronavirus disease (COVID-19) outbreak reported in China in December 2019 has spread throughout the world. The WHO declared it as a pandemic in March 2020. The pandemic severely affected public health and the global economy. Many studies conducted on the coronavirus have helped us to elucidate its pathogenicity and pathophysiology. However, it is important to study the behavior of the pathogen in the environment to develop effective control measures. While studying the persistence and transmission of viruses in drinking water and wastewater systems, a low concentration of coronavirus and its nucleic acids have been detected in municipal wastewaters. This could be due to their high susceptibilities to degradation in aqueous environments. Epidemiological study on coronaviruses in wastewater will serve two purposes, i.e., in early detection of outbreak and in identifying asymptomatic carriers. In such cases, the epidemiological study will help in early detection of the presence of the virus in the community. Secondly, it will help in knowing if there are asymptomatic carriers, as such people do not show any signs of symptoms but shed the viruses in feces. The present review focuses on the epidemiological surveillance of wastewater for coronaviruses, as in recent years these are increasingly causing global pandemics. In this review we have discussed, the four pertinent areas of coronavirus study: (1) occurrence of coronavirus in wastewater, (2) wastewater based epidemiological surveillance of coronaviruses, (3) epidemiological surveillance tools used for detection of coronaviruses in sewage, and (4) persistence and sustainability of coronaviruses in wastewater.Entities:
Keywords: COVID-19; Coronavirus; Environmental monitoring; Epidemiological surveillance; Pandemic; Wastewater
Mesh:
Substances:
Year: 2021 PMID: 34302225 PMCID: PMC8300075 DOI: 10.1007/s10661-021-09303-8
Source DB: PubMed Journal: Environ Monit Assess ISSN: 0167-6369 Impact factor: 2.513
Fig. 1Timeline of detection and characterization of coronavirus
Characteristics of coronaviruses diseases and infections
| Coronaviruses | Diseases / symptoms | Mode of transmission |
|---|---|---|
| Feline enteric coronavirus | Pneumonia, abdominal enlargement, chronic fever | Direct contact, fecal–oral route, sheding feces, body fluid |
| Canine coronavirus | Mild gastroenteritis, diarrhea | Fecal–oral route, small intestinal secretion |
| Transmissible gastroenteritis virus in swine | Mild diarrhea, gastroenteritis | Fecal–oral route, small intestinal secretion, smears |
| Porcine epidemic diarrhea virus | Gastroenteritis, diarrhea, vomiting | Fecal–oral route, intestinal secretion |
| Bovine coronavirus | Gastroenteritis, dehydration, diarrhea, fever | Fecal–oral route, respiratory droplets |
SARS coronavirus Human | Sever acute respiratory syndrome, diarrhea, fever respiratory diseases | Aerosol droplets, fecal–oral route, stool, serum |
| SARS Cv (civet cats, bats) | Subclinical, respiratory diseases | Fecal–oral route, feces |
| Avian infectious bronchitis virus | Nephritis secretion, egg production decreases | Ingestion of food contaminated with feces |
| Turkey coronavirus | Diarrhea, cyanotic skin | Fecal–oral route, intestinal secretion |
Source: Fanner’s Veterinary Virology, 5th Edition, Chapter 24
Fig. 2Molecular platforms used for clinical evaluation of SARS-CoV-2 vaccines
Covid 19 vaccine candidates under phase III clinical trials and authorized for emergency use
| Vaccine platform/vaccine target | Candidate | Considerations and storage temperature | Current stage of clinical trial and dose |
|---|---|---|---|
| RNA vaccines/S protein with two proline substitutions (K986P and V987P) | BNT162b2 from BioNTech/Pfizer | Low cost and simple to develop, requires storage at low temperatures (− 70 to − 10 °C) | Phase III 2 dose in 3 to 4 weeks |
| RNA vaccines/S protein with two proline substitutions (K986P and V987P) | mRNA-1273 from Moderna/NIAID | Low cost and simple to develop, requires storage at low temperatures (− 20 + − 5 °C) | Phase III 2 dose 4 weeks |
| Conventional inactivated vaccines/whole virus | CoronaVac from Sinovac Research and Development Co., Ltd. China | Essential adjuvant is used to boost an immune response, requires storage at low temperatures (2–8 °C) | Phase III 2 dose 4 weeks |
| Conventional inactivated vaccines/whole virus | BBIBP-CorV from Beijing Institute of Biological products, Wuhan Institute of Biological Products and Sinopharm, China | Essential adjuvant is used to boost an immune response, requires storage at low temperatures (2–8 °C) | Phase III 2 dose 4 weeks |
| Conventional inactivated vaccines/whole virus | BBV152 (Covaxin) from Bharat Biotech and Indian Council of Medical Research, India | Essential adjuvant is used to boost an immune response, requires storage at low temperatures (2–8 °C) | Phase III 2 dose 4 weeks |
| Viral vector vaccine/full length S protein | Sputnik V COVID-19 vaccines from Gamaleya Research Institute and Health Ministry of the Russian Federation. Russian | Produces strong immune response and requires storage at low temperatures (2–8 °C). | Phase III a 2 dose in 3 weeks |
| Viral vector vaccine/full length S protein | Oxford-AstraZeneca COVID-19 vaccines (ChAdOx1 nCoV-19, Covishield) from University of Oxford, AstraZeneca, UK (Sweden) | Produces strong immune response and requires storage at low temperatures (2–8 °C). | Phase III 2 dose in 4–12 weeks |
Viral vector vaccine/ Full length S protein | Convidicea vaccine (Ad5-nCoV) from Beijing Institute of Biotechnology, China | Produces strong immune response and requires storage at low temperatures (2–8 °C). | Phase III Single dose |
Viral vector vaccine/ S protein with two proline substitutions (K986P and V987P) and at Furin cleavage sites (R682S and V987P) | Johnson & Johnson COVID-19 vaccine. (Ad26.COV2.s) from Janseen Pharmaceutical companies | Produces strong immune response and requires storage at low temperatures (2–8 °C). | Phase III Single dose |
Peptide vaccine/ RBD-dimer (residues 319–537 as tandem repeat) | ZF2001 (BBD- Dimer) from Anhui Zhifei Longcom Biopharmaceutical and Institute of Microbiology, Chinese Academy of Sciences, China | A consistent safety record in the past, Provided with an adjuvant to boost an immune response, requires storage at low temperatures (2–8 °C). | Phase III 2 dose 2 weeks |
| Peptide vaccine/full length S protein | Novavax COVID-19 (NVX-C0V2373) from Novavax, USA | A consistent safety record in the past, Provided with an adjuvant to boost an immune response, requires storage at low temperatures (2–8 °C). | Phase III |
Occurrence and detection of infectious coronaviruses in water environment
| Virus | Water matrix | Detection method | Country/years | Reference |
|---|---|---|---|---|
| Alpha and Beta corona virus | Surface water (water channels) | Out of 21 samples tested, one was found positive for corona virus by broad range semi-nested RT PCR | Central Saudi Arabia (2015) | Blanco et al., |
| Human coronavirus 229E and Human coronavirus HKU1 | Class B biosolids from waste water treatment facility | 83% of samples tested were positive for corona virus and higher relative abundance was observed in influent samples than in effluents | USA (2011) | Bibby et al., |
| Human coronavirus HKU1 | Influent and effluent sludge | Samples were tested using RT-PCR. N1 fragment was detected in sewage from 6 sites; N3 and E fragment were detected from 2 sites | USA (2013) | Bibby & Peccia, |
| Human coronavirus 229E | Sewage sample from 7 cities and from airport | Virus RNA detected using qRT-PCR | Netherlands (2020) | Mallapaty, |
| SARS CoV-2 | Sewage water of Amsterdam airport and human waste water from Tilburg | Gene fragment of novel coronaviruses in untreated sewage sample from two WWTP detected using RT-qPCR | Netherlands (2020) | Mallapaty, |
| SARS CoV-2 | Untreated sewage sample from suburban pumping station (PS) and two treatment plants (WWTP) from urban catchment of Southeast Queensland | Viral RNA detected in two sample using RT-PCR | Southeast Queensland (SEQ) Australia (2020) | Ahmed et al., |
| SARS CoV-2 | Random collection of sewage sample from pumping stations | Viral RNA identified using RT-PCR | Chennai, India (2020) | Chennai metro water supply and sewage board. (CMWSSB) |
Summary of QMRA associated with viruses in contaminated water sources
| Health hazard identification | • Gastrointestinal diseases results in circulation of enteric viruses in drinking water • Norovirus-viral gastroenteritis is observed in all age groups. Rotavirus causes infection in children. Astrovirus infection leads to diarrhea. Adenoviruses cause acute viral gastroenteritis in children. Enteroviruses cause meningitis, encephalitis, and poliomyelitis. |
| Exposure assessment | • Level of exposure reveled by the comparative study of volume of ingested water per day with concentration of enteric viruses in drinking water • Level of water concentration estimated will help in monitoring the health risk assessment • Varies in combination of log reduction carried out through treatment process • Pathogens exposure was examined and reduction of pathogen attained by developing and applying benchmark measures |
| Dose response assessment | • Predictable health hazard is attained by adaptation of dose response model • Dose response model helped in calculating the probability of infection and risk of illness after exposure of viruses • Dose response model developed and applied for rotavirus, is used in risk assessment and the data are characterized by beta-Poisson models |
| Risk quantification | • Characterization of risk in this report guided to maintain the minimum of 4 log reduction to all drinking water • Level of virus reduction in water source is calculated by site specific assessment, which helps in monitoring water source and estimating the contamination or risk • Increased viruses concentration in water is always demands for greater reduction |
Source: Enteric viruses in drinking water, document for public consultation, prepared by the Federal-Provincial-Territorial Committee on Drinking Water, Canada, 2017
Analytical methods used for detection of SARS-CoV-2 in wastewaters
| Sampling process | RNA isolation | Detection and quantification of RNA | Reference |
|---|---|---|---|
24-h flow-dependent composite Centricon® Plus-70 centrifugal ultrafilters | RNeasy PowerMicrobiome Kit | RT-qPCR 2.6–2.2 × 103 copies/L | Medema et al., |
24-h flow-dependent composite Ultrafiltration | NucleoSpin RNA Virus kit | RT-qPCR and Sanger sequencing analysis 30–200 gene equivalents/L | Westhaus et al., |
Refrigerated autosampler, submersible in situ high frequency autosampler and grab sampling | Direct RNA extraction from electronegative membranes | RT-qPCR N_Sarbeco RT-qPCR Sanger and Illumina sequencing 8.3 copies/reaction | Corman et al., |
Composite samples, autosampler, ultrafiltration with spin concentrators | RNeasy Mini Kit (QIAGEN) | qRT-PCR Nanopore and sanger sequencing | Nemudryi et al., |
| NanoCeram column filters | Viral RNA QIAGEN Kit | RT-qPCR 104–105 genomic copies/L | Miyani et al., |
Composite sampling precipitated with polyethylene glycol 8000 (PEG), 0.2-μm-filtration | Trizol (Thermofisher) | RT-qPCR Sanger sequencing | Wu et al., |
Grab and pool PEG 9000 | NucleoSpin® RNA Virus | TaqPath™ Covid-19 RT-PCR Kit 5.6 × 10–3.5 × 102 copies/L | Kumar et al., |
Composite sampling for 24 h Ultrafiltration PEG 8000 | ABIOpure Viral DNA/RNA Extraction kits (Alliance Bio Inc) TRIzol | RT-qPCR 31.7 gene copies/mL | Hasan et al., |
Grab (0.2 L) Aluminum-driven flocculation Grab (0.5–1 L) Aluminum hydroxide adsorption-precipitation protocol Centrifugation at 1900 × g for 30 min | Nucleo-Spin RNA virus kit | RT-qPCR 1.6–9.7 × 105 copies/L TaqMan real-time RT-PCR 6.3 × 104–6.3 × 105 copies/L | Randazzo et al., |
Composite sampling Centrifugated at 200,000 × g for 1 h at 4 °C using XPN80 (Coulter Beckman) | PowerFecal Pro kit (QIAGEN) | RT-qPCR 5.104 GU/L to 3.106 GU/L | Wurtzer et al., |
Composite sampling centrifugation at 3000 × Filtration (Nalgene Rapid-flow™ 0.45 µM filter) Concentrated using Centriprep centrifugal filter units (Merck) | High Pure viral RNA kit (Roche Life Science, Mannheim, Germany) | RT-qPCR 3.50 and 4.20 Log10 gc/L | Martin et al., |
Grab sampling influent post grit solids and primary clarified sludge | GeneRotex automated nucleic acid extraction system | RT-qPCR RT-ddPCR (2 copies/reaction) | D'Aoust et al., |
Composite sampling using fixed-site sampler NanoCeram filter flocculation and adsorption | DNeasy Blood and Tissue kit (Qiagen) | RT-qPCR 7300 fast real-time PCR system 3.6 × 108 genomes per 5µL | Saguti et al., |
Grab sampling aluminum-based adsorption precipitation | Maxwell RSC Pure Food GMO and Authentication Kit (Promega) | RT-qPCR using One Step PrimeScript™ RT-PCR Kit Illumina sequencing | Perez-Cataluna et al., |
Composite sampling Concentrated using 100 kDa Centricon ultrafilters | Nuclisens kit (bioMérieux) | Multiplex PCR Nanopore and Illumina sequencing | Izquierdo-Lara et al., |
| Grab sampling | GeneRotex automated nucleic acid extraction system | qPCR assays 500 copies/mL | Zhou et al., |
24-h composite sampling Centrifugation Ultrafiltration through Centricon® Plus-70 centrifugal ultrafilters | magnetic extraction reagents from Biomerieux Nuclisens kit (Biomerieux) | RT-ddPCR 2.7 copies of B.1.351 variant and 2.3 copies of wild-type | Heijnen et al., |
24-h composite sampling PEG-dextran method | NucliSENS miniMAG semi-automated extraction system | Three different nested RT-PCR assays, one real-time qPCR assay and direct nucleotide sequencing using the Sanger method 102–5.6 × 104 copies/L | La Rosa et al., La Rosa et al., |
Grab sampling Adsorption-extraction (pH = 4; neutral pH; 25 mM MgCl2) Centrifugal filter (Amicon ultra-15 (30 K); Centricon Plus-70) Polyethylene glycol (PEG 8000) precipitation Ultracentrifugation | RNeasy PowerMicrobiome Kit | TaqMan-based RT-qPCR 19–120 copies/L | Ahmed et al., |
24-h composite and grab sampling Electronegative membranes Ultrafiltration | RNeasy PowerWater Kit and RNeasy PowerMicrobiome Kit | RT-qPCR Sequencing with Illumina and Sanger | Ahmed et al., |
Weekly pooled 24 h and grab InnovaPrep Concentrating Pipette Select Electronegative filtration | Armored RNA Quant (protocol B 2.0.1 with modifications) | Reverse transcription droplet digital PCR (RT-ddPCR) 102–105 copies/L | Gonzalez et al., |
Grab Electronegative membrane-vortex Filtration with mixed cellulose-ester membrane | QIAamp Viral RNA Mini Kit and RNeasy PowerWater Kit | RT-qPCR, Nested PCR and Sanger sequencing 1.8 × 105–1.0 × 108 copies/L | Haramoto et al., |
24-h composite (time or flow dependent) Direct flocculation | NucliSENS® miniMAG® system | EliGene COVID19 Basic A RT kit | Mlejnkova et al., |
| Grab sampling | QIAMP Viral RNA mini kit | T-qPCR, whole genome sequencing and Ion Torrent PGM | Rimoldi et al., |
24-h composite and grab Ultrafiltration Centricon® Plus-70 centrifugal filter Electronegative membrane | ZR Viral RNA Kit | RT-qPCR 3.1–7.5 × 103 copies/L | Sherchan et al., |
Target genes, primers and probes approved by CDC for SARS-CoV-2 detection by PCR in wastewaters
| Target Gene | Primers and probes |
|---|---|
| N- Sarbeco protein | F-CACATTGGCACCCGCAATC R-GAGGAACGAGAAGAGGCTTG P-FAM-ACTTCCTCAAGGAACAACATTGCCA-BHQ1 |
| THREE regions of nucleocapsid (N) gene (CDC) | 2019-nCoV_N1–F: GAC CCC AAA ATC AGC GAA AT 2019-nCoV_N1-R: TCT GGT TAC TGC CAG TTG AAT CTG 2019-nCoV_N1–P: FAM-ACC CCG CAT TAC GTT TGG TGG ACC-BHQ1 2019-nCoV_N2 Forward Primer TTA CAA ACA TTG GCC GCA AA 2019-nCoV_N2 Reverse Primer GCG CGA CAT TCC GAA GAA 2019-nCoV_N2 Probe FAM-ACA ATT TGC CCC CAG CGC TTC AG-BHQ1 2019-nCoV_Forward Primer: AGA TTT GGA CCT GCG AGC G 2019-nCoV_Reverse Primer: GAG CGG CTG TCT CCA CAA GT 2019-nCoV_F Probe: FAM – TTC TGA CCT GAA GGC TCT GCG CG – BHQ-1 FW GGGGAACTTCTCCTGCTAGAAT RW CAGACATTTTGCTCTCAAGCTG probe 5′-FAM- TTGCTGCTGCTTGACAGATT-TAMRA-3′ |
| Envelope protein (E) gene | E_Sarbeco_F: ACAGGTACGTTAATAGTTAATAGCGT E_Sarbeco_R: ATATTGCAGCAGTACGCACACA E_Sarbeco_PROBE: FAM-ACACTAGCCATCCTTACTGCGCTTCG-BBQ |
| ORF1ab | FW1 GTGCTAAACCACCGCCTG REV1 CAGATCATGGTTGCTTTGTAGGT FW2 CGCCTGGAGATCAATTTAAACAC REV2 ACCTGTAAAACCCCATTGTTGA FW CCCTGTGGGTTTTACACTTAA RW ACGATTGTGCATCAGCTGA probe 5′-FAM-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-3 |
| RdRP | RdRP_SARSr-F2 GTGARATGGTCATGTGTGGCGG |
| S | WuhanCoV-spk1-F: TTGGCAAAATTCAAGACTCACTTT WuhanCoV-spk2-R: TGTGGTTCATAAAAATTCCTTTGTG |
Advantages and disadvantages of some of the detection techniques used for detection of viruses in wastewater
| Virus detection and analysis methods | Advantage | Disadvantages |
|---|---|---|
| PCR | • Accurate and high specificity • Detection in short duration of time | • Unable to detect diverse viruses at a time • Unable to isolate single virus from a sample • Humic acid activities control the reaction • Requires more primers and its mutual interference may leads to difficulties in detecting virus • Can be used only for known organisms • Low sensitivity |
| ELISA | • It is cost effective • Relatively simple • Shows high specificity | • Concentration of sample is mandatory • Hidden epitopes present in protein structure leads to inefficiency in test results • Bacteria present in the samples may influence the results |
| Plaque forming test | • Pathogenic and nonpathogenic viruses screening is easy • High sensitivity with short duration | • High analysis costs • Difficulties associated with plaque observation • Time-consuming |
| Nucleic acid sequence based amplification | • Highly specific and accurate • Can amplify more copies in short duration | • Concentration of sample is mandatory • Can be used for only known viruses, it has limit of detection |
| Biosensors | • It enables fast and cheap detection and analysis of virus • Does not require special laboratory facilities and manual sample preparation • Size of biosensor makes it easy to transport, requires less volume of samples, and reagents • Good results with intermolecular observation in real time • Highly sensitive method | • Still in research phase |
| Plaque forming test combined with PCR | • Easy screening of pathogen and nonpathogenic viruses • Enables removal of PCR inhibitors | None |
Persistence and sustainability of corona viruses in wastewater environment
| Viruses | Water matrixes | Results | References |
|---|---|---|---|
| Transmissible gastroenteritis virus (TGEV) | Reagent-grade water and lake water | The TGEV were reduced by 99.9% after 33 days and at 25 °C. In regent grade water neither TGEV | Casanova et al., |
| Pasteurized settled human sewage | In pasteurized water TGEV WERE reduced by 99.9% after 14 days at 25 °C | ||
| Murine hepatitis virus, strain A59 | Waste water and pasteurized water | In waste water at 25 °C, MHV was reduced by 90% after 13 + -1 h: at 10 °C, 90% reduction was reached after 36 + -5 h In pasteurized wastewater at 25 °C, MHV was reduced by 90% after 19 + -8 h: at 10 °C, 90% reduction was predicted. In non-enveloped viruses 90% reduction was predicted | Ye et al., |
Human coronavirus 229E (HCoV), ATCC-740 Feline infectious peritonitis virus (FIPV), ATCC-990 | Pasteurized wastewater and tap water | In the pasteurized water at 23 °C, HCoV and FIPV reduction by 99.9% was reached after 12.1 and 12.5 days. In tap water at 4 °C, HCoV and FIPV reduction by 99.9% was predicted after > 100 days | Gundy et al., |
| Human coronavirus 229E (HCoV), ATCC-740Feline infectious peritonitis virus (FIPV), ATCC-990 | Filtered (0.2 μm) tap water,. Filtered (0.2 μm) primary sludge effluent Activated sludge (secondary sludge, prior to chlorination) effluent | Coronaviruses reduction was quicker in filtered tap water than in tap water (organic matter and suspended solids can provide protection for viruses in water). In wastewater (primary and secondary sludge) at 23 °C, coronaviruses decrease by 99.9% in 2.77–3.54 days. In tap water (both filtered and unfiltered) at 23 °C, PV-1 survives six times longer than coronaviruses. In wastewater (primary and secondary sludge), PV-1 survives 2 to 3 times longer than coronaviruses | Gundy et al., |